News Archive - Page 5 of 7

Information from Lifecare – September 2021

September 2, 2021
Lifecare’s activities in the period after the shareholder letter distributed July 2nd, 2021 have been focused on streamlining the continued development of the Sencell technology and to continue to ensure organizational adjustments with the aim to optimize the R&D set-up. In addition, the Board and administration of Lifecare have focused on financial preparations ensuring operational […]
Read more

Open Position – Scientific Project Manager QA/QC

September 1, 2021
Lifecare AS (lifecare.attme.dev) is a listed Norwegian company with operations in Germany (Rhine-Main Area). The company is engaged in the development of innovative biosensors based on MEMS and NEMS technologies. The current flagship product is a very small implantable continuous glucose sensor with ultra-long duration of use for patients with Diabetes mellitus. Lifecare is currently […]
Read more

Acquisition of laboratory – report and declaration from the Board

August 27, 2021
§ 3-8 erklæring signert § 3-8 redegjørelse signert Uttalelse fra revisor
Read more

Acquisition of Laboratory. From customer to full control.

August 27, 2021
Lifecare has signed a term sheet to acquire the laboratory of Pfützner Science & Health Institute GmbH (the “Lab”) for a total consideration of up to Euro 1.175 million of which Euro 100,000 will be paid in cash, Euro 300,000 will be settled in new shares in Lifecare, and the remaining part of the consideration, […]
Read more

Notification of Extraordinary General Meeting regarding a potential private placement of new shares

August 27, 2021
The Board of Directors (the “Board”) of Lifecare AS (the “Company” or “Lifecare”) has passed a resolution convening an Extraordinary General Meeting to be held on 10 September 2021 to approve a board authorization for a share capital increase of up to 25% of the Company’s current share capital (the “Board Authorisation”). ‍ Lifecare has engaged Carnegie […]
Read more

The European Patent Office grants new Lifecare patent

August 3, 2021
The European Patent Office (EPO) has as expected decided to grant Lifecare a new patent for an updated sensor measuring system. The now approved patent expands Lifecare’s protection in time and scope. As announced in Lifecare’s press release 25.03.21, the EPO by then intended to grant this patent, about an “interstitial fluid osmotic pressure […]
Read more

Information to the shareholders

July 2, 2021
The spring and early summer has been busy in Lifecare. In addition to continued development of the Sencell technology, the activity during this period has included preparation and implementation of necessary organizational adjustments, including clarifications and negotiations related to Digital Diagnostics AG and the acquisition of Cantimed UG. Lifecare’s annual general meeting was held […]
Read more

Open Position – Leading Senior Scientist Nanotechnology Development

June 30, 2021
Lifecare AS (lifecare.attme.dev) is a stock listed Norwegian company with operations in Germany (Rhine-Main Area and Northern Germany). The company is engaged in the development of innovative biosensors based on MEMS and NEMS technologies. Current flagship product is a very small implantable continuous glucose sensor with ultra-long duration of use for patients with Diabetes mellitus. […]
Read more

Lifecare AS acquires Cantimed UG and broadens its biosensing capabilities

June 24, 2021
Lifecare AS has acquired 100% ownership of the German company Cantimed UG, following a share purchase agreement with Nanoscale Systems Nanoss GmbH. The transaction includes a license ensuring Lifecare´s access to the patented Nano3DSense technology in the medical field. This implies a continuation of Lifecare’s license covering the field of diabetes originally established in 2018 […]
Read more

Lifecare AS prolongs and amplifies collaboration with Bath University.

June 22, 2021
Lifecare is happy to announce that the collaboration with the Chemistry Department of Bath University, UK, has been prolonged and further amplified. This will ensure mutual beneficiary progress on the development of proprietary specific chemistry solutions for detection of glucose and additional analytes of interest based on the Sencell technology. In addition, Lifecare has directly […]
Read more